Weekly Cardiology Research Analysis
This week’s cardiology literature was dominated by high‑quality randomized trials refining antithrombotic duration after PCI and device therapies for valvular disease, alongside mechanistic imaging evidence reshaping our understanding of right‑heart remodeling. Two large RCTs provide practice‑relevant guidance on shortening or extending antithrombotic therapy in distinct clinical scenarios, while randomized imaging data clarify durable hemodynamic benefits after transcatheter tricuspid replaceme
Summary
This week’s cardiology literature was dominated by high‑quality randomized trials refining antithrombotic duration after PCI and device therapies for valvular disease, alongside mechanistic imaging evidence reshaping our understanding of right‑heart remodeling. Two large RCTs provide practice‑relevant guidance on shortening or extending antithrombotic therapy in distinct clinical scenarios, while randomized imaging data clarify durable hemodynamic benefits after transcatheter tricuspid replacement. Across the week, there was also strong momentum toward integrating advanced imaging, AI, and pragmatic screening to enable earlier, personalized prevention.
Selected Articles
1. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
OPTIMA‑AF randomized 1,079 AF patients undergoing intravascular imaging‑guided PCI to either 1‑month dual therapy (DOAC + P2Y12) followed by DOAC monotherapy or 12‑month dual therapy. One‑month therapy was non‑inferior for death or thromboembolic events at 12 months and significantly reduced major or clinically relevant non‑major bleeding, suggesting a favorable net clinical profile in this population.
Impact: Provides randomized, practice‑defining evidence on antithrombotic duration specifically for AF patients undergoing imaging‑guided PCI, demonstrating bleeding reduction without loss of efficacy.
Clinical Implications: In AF patients treated with imaging‑guided PCI, clinicians can consider a 1‑month dual‑therapy strategy followed by DOAC monotherapy to minimize bleeding while preserving thromboembolic protection, with attention to individual ischemic/bleeding risk and local practice.
Key Findings
- One‑month dual therapy (DOAC + P2Y12) followed by DOAC monotherapy was non‑inferior to 12 months for death or thromboembolism at 12 months.
- The 1‑month regimen significantly reduced major or clinically relevant non‑major bleeding.
- Multicenter RCT across 75 sites in Japan with 1,079 patients (median age 76).
2. Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
In 8,250 patients with multivessel coronary disease who were event‑free after 12 months post‑DES, extending DAPT (clopidogrel + aspirin) to 24 months reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.82) versus aspirin alone, without increasing clinically relevant bleeding over median 34.3 months.
Impact: A very large randomized trial showing tailored DAPT extension in anatomically high‑risk patients reduces ischemic events without more bleeding — likely to influence guideline recommendations for multivessel disease.
Clinical Implications: Consider extending DAPT to 24 months in selected, event‑free multivessel CAD patients after individualized bleeding risk assessment; integrate intravascular imaging and patient factors into shared decision‑making.
Key Findings
- Primary composite at 36 months: 5.8% with extended DAPT vs 6.8% with aspirin alone (HR 0.82; P=0.03).
- Clinically relevant or major bleeding (BARC ≥2) did not increase (1.4% vs 1.5%).
- Randomized 8,250 patients across 97 centers; median follow‑up 34.3 months.
3. TRISCEND II: Effect of Transcatheter Tricuspid Valve Replacement on Echocardiographic Measures of Right Heart Remodeling and Function.
TRISCEND II randomized 400 patients with severe symptomatic tricuspid regurgitation to EVOQUE TTVR versus medical therapy and reported 1‑year core‑lab echo outcomes: >95% of TTVR patients had mild TR at discharge and sustained to 1 year, with reduced IVC diameter, RV reverse remodeling, and increased RV stroke volume and cardiac output despite expected preload unloading effects on systolic indices.
Impact: A rigorously conducted RCT providing mechanistic and hemodynamic evidence that TTVR produces durable TR elimination and meaningful right‑heart remodeling and forward flow improvements, strengthening the therapeutic rationale for TTVR in selected patients.
Clinical Implications: Supports use of TTVR (EVOQUE) for appropriately selected patients with severe symptomatic TR to achieve durable TR reduction, reduce venous congestion, and improve forward flow; clinicians should counsel patients about expected RV preload‑related changes in systolic indices.
Key Findings
-
95% of TTVR patients had mild TR at discharge and sustained to 1 year versus 2.3% in controls at 1 year.
- Inferior vena cava diameter decreased significantly and RV diastolic size improved after TTVR.
- RV stroke volume and cardiac output increased significantly despite reductions in preload‑dependent systolic indices.